Oliveira Jose M, Gomes Catarina, Faria Diogo B, Vieira Tiago S, Silva Fernando A, Vale Joana, Pimentel Francisco L
Lenitudes Medical Center and Research, Sta. Maria Feira, Porto, Portugal; HPP - Nuclear Medicine, Porto, Portugal.
Lenitudes Medical Center and Research, Sta. Maria Feira, Porto, Portugal.
World J Nucl Med. 2017 Jan-Mar;16(1):3-7. doi: 10.4103/1450-1147.198237.
The Ga-prostate-specific membrane antigen ( Ga-PSMA) has been recently developed to be used, as a ligand, in positron emission tomography/computed tomography (PET/CT) prostate cancer imaging, to detect prostate disease. The main objective of this review was to collect data and findings from other studies and articles to assess, theoretically, if GA-PSMA PET/CT is a more appropriate prostate cancer diagnostic technique in comparison with others available such as CT, F-fluoro-2-deoxyglucose PET/CT, or F-fluoromethylcholine ( F-choline) PET/CT. For that purpose, PubMed, the online scientific articles' database, was consulted where the keywords "PSMA" and "PET" were used to find relevant articles. The clinicaltrials.gov, clinical trials' database, was also consulted where the keywords "Ga-PSMA" and "prostate" were used to search clinical trials. Based on the reviewed scientific literature, several studies were conducted to assess and compare the Ga-PSMA PET/CT detection rate in prostate cancer with other available techniques. One of those studies, conducted by Giesel ., concluded, within study sample, that 75% of patients with lymph nodes detected by Ga-PSMA PET/CT would have not been identified using other conventional morphological criteria based techniques. In Eiber .'s study, Ga-PSMA PET detected prostatic disease findings in 67% of patients with prostate-specific antigen levels <1 ng/mL, when compared with choline-based PET that presented detection rates between 19% and 36%. In Bluemel .'s study, Ga-PSMA identified positive prostatic disease in 43.8% of the patients with negative findings in F-choline PET/CT. Findings from this review demonstrate that Ga-PSMA PET/C is more effective in detecting metastases, lymph nodes, and recurrent prostate cancer when compared to F-choline-based PET/CT and CT. Ga-PSMA PET/CT presents also more imaging contrast and can be more cost-effective. Ga-PSMA has already been subjected to first-in-human trials, and it is now being tested in Phase II and III trials.
镓标记的前列腺特异性膜抗原（Ga-PSMA）最近被开发用作正电子发射断层扫描/计算机断层扫描（PET/CT）前列腺癌成像中的一种配体，用于检测前列腺疾病。本综述的主要目的是收集其他研究和文章的数据与发现，从理论上评估与其他可用技术（如CT、F-氟代脱氧葡萄糖PET/CT或F-氟甲基胆碱（F-胆碱）PET/CT）相比，Ga-PSMA PET/CT是否是一种更合适的前列腺癌诊断技术。为此，查阅了在线科学文章数据库PubMed，使用关键词“PSMA”和“PET”查找相关文章。还查阅了临床试验数据库clinicaltrials.gov，使用关键词“Ga-PSMA”和“前列腺”搜索临床试验。基于所综述的科学文献，进行了多项研究以评估和比较Ga-PSMA PET/CT与其他可用技术在前列腺癌中的检测率。其中一项由吉泽尔等人进行的研究得出结论，在研究样本中，通过Ga-PSMA PET/CT检测到淋巴结的患者中，75%使用其他基于传统形态学标准技术无法识别。在艾伯等人的研究中，与基于胆碱的PET（检测率在19%至36%之间）相比，Ga-PSMA PET在67%的前列腺特异性抗原水平<1 ng/mL的患者中检测到前列腺疾病发现。在布卢梅尔等人的研究中，Ga-PSMA在F-胆碱PET/CT检查结果为阴性的患者中，有43.8%检测出前列腺疾病呈阳性。本综述的结果表明，与基于F-胆碱的PET/CT和CT相比，Ga-PSMA PET/C在检测转移灶、淋巴结和复发性前列腺癌方面更有效。Ga-PSMA PET/CT还具有更高的成像对比度，并且可能更具成本效益。Ga-PSMA已经进行了首次人体试验，目前正在进行II期和III期试验。
